Dr. George Schreiner has been associated with innovative biotech companies for over 15 years. He has diverse Drug Discovery and Development experience, most recently as CEO of Raven Biotechnologies.
Prior to this he was President, Scios Inc. /Johnson & Johnson, member of the Pharmaceutical R&D Committee, Johnson & Johnson and Chaired the Early Discovery and Development Committee at Johnson & Johnson. He was Chief Scientific Officer and Chief Medical Officer at Scios Inc and was instrumental in the implementation of the Research and Discovery programs at Scios that led to the merger with Johnson & Johnson in 2002. Dr. Schreiner started his career in industry as Vice President, Medical Science and Preclinical Research at CV Therapeutics. Dr. Schreiner is a member of several corporate boards including: Metabasis Therapeutics, a publicly held company specializing in small molecule therapeutics targeting diabetes, hyperlipidemia, and liver diseases; Chairman of the Board, PROOF, a Canada-funded National Center of Excellence in biomarkers focused on chronic diseases of the heart, lung, and kidneys and the Silicon Valley Branch of the Juvenile Diabetes Research Foundation. Over the past 25 years Dr. Schreiner has held academic positions at Brigham and Women's Hospital, Harvard Medical School, Boston, MA, Washington University School of Medicine, St. Louis, MO and Stanford University, Palo Alto, CA. Dr. Schreiner is a co-author on 135 publications and a co-inventor on filed 26 patents. Dr. Schreiner, is a graduate of Harvard Medical School, Boston, MA with an MD and Harvard University, Cambridge, MA with a Ph.D. in immunology.